stockportfolio.pro
Cytek Biosciences, Inc. (CTKB)
Healthcare · Medical Devices · NasdaqGS
Cytek Biosciences, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $710,000 | $2.18M | $164.04M | $193.39M | $200.45M | $201.49M |
| Gross profit | $51.71M | $79.14M | $100.97M | $109.43M | $111.11M | $104.46M |
| Net income | $19.41M | $3.03M | $2.58M | $-11.33M | $-6.02M | $-66.54M |
| Net margin | 2733.9% | 138.8% | 1.6% | -5.9% | -3.0% | -33.0% |
Source: Cytek Biosciences, Inc. SEC filings (10-K).
Explore 6 years of Cytek Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CTKB in your portfolio →
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Cytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s revenue?
Cytek Biosciences, Inc. (CTKB) reported revenue of $201.49M for fiscal year 2025, up 0.5% from the prior year, according to its SEC filings.
Is Cytek Biosciences, Inc. profitable?
No — CTKB reported a net loss of $-66.54M in fiscal 2025.
What is CTKB's P/E ratio?
Cytek Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Cytek Biosciences, Inc. growing?
CTKB's revenue grew at roughly 209.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Cytek Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.